Last reviewed · How we verify
Intravenous magnesium sulfate infusion
Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility.
Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility. Used for Eclampsia and pre-eclampsia prevention and treatment, Seizure prophylaxis in high-risk obstetric patients, Neuroprotection in acute ischemic stroke.
At a glance
| Generic name | Intravenous magnesium sulfate infusion |
|---|---|
| Sponsor | Chinese University of Hong Kong |
| Drug class | Electrolyte/mineral supplement; anticonvulsant; vasodilator |
| Target | NMDA receptor; L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Neurology; Obstetrics; Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Intravenous magnesium sulfate works by blocking calcium influx into cells and antagonizing N-methyl-D-aspartate (NMDA) receptors, which reduces neuronal hyperexcitability and peripheral vasoconstriction. It also stabilizes cell membranes and modulates neurotransmitter release, making it effective for conditions involving excessive neuronal activity or vasospasm.
Approved indications
- Eclampsia and pre-eclampsia prevention and treatment
- Seizure prophylaxis in high-risk obstetric patients
- Neuroprotection in acute ischemic stroke
Common side effects
- Flushing
- Hypotension
- Hypermagnesemia
- Muscle weakness
- Nausea
- Respiratory depression (at high doses)
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Magnesium vs. Dexmedetomidine in TURBT Under Spinal Anesthesia (NA)
- Intravenous Lidocaine, Ketamine, and Magnesium in Thoracic Surgery
- Lidocaine vs Magnesium Sulfate for Hemodynamic Stability During Emergence in Infertility-Related Laparoscopic Surgery" (NA)
- Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial (NA)
- Intravenous Administration of Magnesium Sulfate in Laparoscopic Hysterectomy Cases (NA)
- Magnesium Trial in Acute Asthma in Emergency Department (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: